Cargando…
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa
BACKGROUND: To apply clarithromycin as an immunomodulatory treatment in experimental urosepsis by multidrug-resistant Pseudomonas aeruginosa. METHODS: Acute pyelonephritis was induced in 40 rabbits after inoculation of the test isolate in the renal pelvis. Therapy was administered upon signs of seps...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1397846/ https://www.ncbi.nlm.nih.gov/pubmed/16504031 http://dx.doi.org/10.1186/1471-2334-6-31 |
_version_ | 1782126974881234944 |
---|---|
author | Giamarellos-Bourboulis, Evangelos J Antonopoulou, Anastasia Raftogiannis, Maria Koutoukas, Pantelis Tsaganos, Thomas Tziortzioti, Vassiliki Panagou, Charalambos Adamis, Theodoros Giamarellou, Helen |
author_facet | Giamarellos-Bourboulis, Evangelos J Antonopoulou, Anastasia Raftogiannis, Maria Koutoukas, Pantelis Tsaganos, Thomas Tziortzioti, Vassiliki Panagou, Charalambos Adamis, Theodoros Giamarellou, Helen |
author_sort | Giamarellos-Bourboulis, Evangelos J |
collection | PubMed |
description | BACKGROUND: To apply clarithromycin as an immunomodulatory treatment in experimental urosepsis by multidrug-resistant Pseudomonas aeruginosa. METHODS: Acute pyelonephritis was induced in 40 rabbits after inoculation of the test isolate in the renal pelvis. Therapy was administered upon signs of sepsis in four groups: A, controls; B, intravenous clarithromycin; C, amikacin; and D, both agents. Survival and vital signs were recorded; blood was sampled for culture and estimation of pro-inflammatory mediators; monocytes were isolated for determination of apoptotic rate and ex vivo TNFα secretion. Quantitative cultures and biopsies of organs were performed after death. RESULTS: Increased rectal temperature and oxygen saturation were found in groups B and D compared to A and C. Mean survival of groups A, B, C and D was 2.65, 7.15, 4.25 and 8.70 days respectively. No differences were noted between groups concerning bacterial load in blood and tissues and serum endotoxins. Serum MDA and total caspase-3 activity of monocytes of group D decreased following treatment compared to other groups. Negative correlation was detected between cytoplasmic caspase-3 and ex vivo secretion of TNFα of blood monocytes of group A; similar correlation was not found for any other group. Pathology scores of liver and lung of group B were lower than group A. CONCLUSION: Clarithromycin administered late in experimental urosepsis by multidrug-resistant P. aeruginosa prolonged survival and ameliorated clinical findings. Its effect is probably attributed to immunomodulatory intervention on blood monocytes. |
format | Text |
id | pubmed-1397846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-13978462006-03-11 Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa Giamarellos-Bourboulis, Evangelos J Antonopoulou, Anastasia Raftogiannis, Maria Koutoukas, Pantelis Tsaganos, Thomas Tziortzioti, Vassiliki Panagou, Charalambos Adamis, Theodoros Giamarellou, Helen BMC Infect Dis Research Article BACKGROUND: To apply clarithromycin as an immunomodulatory treatment in experimental urosepsis by multidrug-resistant Pseudomonas aeruginosa. METHODS: Acute pyelonephritis was induced in 40 rabbits after inoculation of the test isolate in the renal pelvis. Therapy was administered upon signs of sepsis in four groups: A, controls; B, intravenous clarithromycin; C, amikacin; and D, both agents. Survival and vital signs were recorded; blood was sampled for culture and estimation of pro-inflammatory mediators; monocytes were isolated for determination of apoptotic rate and ex vivo TNFα secretion. Quantitative cultures and biopsies of organs were performed after death. RESULTS: Increased rectal temperature and oxygen saturation were found in groups B and D compared to A and C. Mean survival of groups A, B, C and D was 2.65, 7.15, 4.25 and 8.70 days respectively. No differences were noted between groups concerning bacterial load in blood and tissues and serum endotoxins. Serum MDA and total caspase-3 activity of monocytes of group D decreased following treatment compared to other groups. Negative correlation was detected between cytoplasmic caspase-3 and ex vivo secretion of TNFα of blood monocytes of group A; similar correlation was not found for any other group. Pathology scores of liver and lung of group B were lower than group A. CONCLUSION: Clarithromycin administered late in experimental urosepsis by multidrug-resistant P. aeruginosa prolonged survival and ameliorated clinical findings. Its effect is probably attributed to immunomodulatory intervention on blood monocytes. BioMed Central 2006-02-21 /pmc/articles/PMC1397846/ /pubmed/16504031 http://dx.doi.org/10.1186/1471-2334-6-31 Text en Copyright © 2006 Giamarellos-Bourboulis et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Giamarellos-Bourboulis, Evangelos J Antonopoulou, Anastasia Raftogiannis, Maria Koutoukas, Pantelis Tsaganos, Thomas Tziortzioti, Vassiliki Panagou, Charalambos Adamis, Theodoros Giamarellou, Helen Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title | Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title_full | Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title_fullStr | Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title_full_unstemmed | Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title_short | Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa |
title_sort | clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant pseudomonas aeruginosa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1397846/ https://www.ncbi.nlm.nih.gov/pubmed/16504031 http://dx.doi.org/10.1186/1471-2334-6-31 |
work_keys_str_mv | AT giamarellosbourboulisevangelosj clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT antonopoulouanastasia clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT raftogiannismaria clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT koutoukaspantelis clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT tsaganosthomas clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT tziortziotivassiliki clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT panagoucharalambos clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT adamistheodoros clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa AT giamarellouhelen clarithromycinisaneffectiveimmunomodulatorwhenadministeredlateinexperimentalpyelonephritisbymultidrugresistantpseudomonasaeruginosa |